Obseva: The power of the GnRH antagonist MoA to personalize fibroid management

• Introduction – The E2 theory and Linzagolix: a new oral GnRH antagonist, Felice Petraglia (Italy)
• Heavy menstrual bleeding due to uterine fibroids: Lingazolix efficacy and safety, Hugh Taylor (USA)
• Hormonal add-back therapy in the treatment of uterine fibroids, Jacques Donnez (Belgium)